Nurix Therapeutics Signs $2.3 Billion Roche Collaboration for BTK Degrader Bexobrutideg

A $700 million upfront payment and a co-development cost-share structure signal that Nurix Therapeutics has secured one of the most consequential targeted protein degradation partnerships to date, with manufacturing and GMP readiness implications that extend well beyond the two companies. The global license and collaboration agreement with Roche, covering bexobrutideg (NX-5948) across malignant hematology, immunology, and neurology, positions a clinical-stage BTK degrader for multi-indication scale-up under a framework that will test specialized CMO capacity across the sector.

Under the agreement, development costs are split 40% Nurix / 60% Roche, with U.S. profits and losses shared equally and tiered royalties applied to ex-U.S. sales. Potential total payments reach $2.3 billion, inclusive of the upfront. Closing remains subject to Hart-Scott-Rodino antitrust clearance and other customary conditions, with the $700 million payment expected within 30 days of agreement effectiveness. Pro-forma cash, including that payment, is projected at approximately $1.14 billion against a current balance of $443.5 million as of May 31, 2026.

For QA directors and process development leads, the collaboration's scope is the operative detail. Planned Phase 2 studies in multiple sclerosis and chronic spontaneous urticaria, layered onto the ongoing registrational program in chronic lymphocytic leukemia, mean that bexobrutideg's manufacturing process will need to support parallel indication-specific clinical supply chains under 21 CFR Part 211 and applicable ICH Q10 quality system requirements. Targeted protein degraders, as a modality, carry distinct analytical and process validation challenges compared with conventional small molecules, particularly around heterobifunctional linker characterization and degrader ternary complex assay development.

Clinical data presented at the European Hematology Association (EHA) 2026 meeting from the NX-5948-301 Phase 1a/1b study reinforce the development rationale. Updated Phase 1a results showed a median progression-free survival of 22.1 months and an objective response rate of 83% across relapsed/refractory CLL/SLL patients, including those with BTK resistance mutations and high-risk molecular features. Phase 1b results reported an ORR of 92.9% among evaluable patients, with 18 of 19 responding.

The cost-share model and multi-indication expansion plan will drive near-term demand for GMP-compliant manufacturing capacity in the degrader space, a segment where qualified CMO infrastructure remains limited relative to the volume of programs now entering late-stage development.

The measurable checkpoint to watch is antitrust clearance timing, which will determine when the $700 million payment lands and when the co-development operational structure formally activates.

Source: Nurix Therapeutics via GlobeNewswire, July 9, 2026.